Clinical Trial Update: Brentuximab Vedotin in Combination With CHEP in Patient With PTCL [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Brentuximab Vedotin in combination with CHEP for peripheral T-cell lymphoma is in early stages with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• CHEP

Snippet

Sponsor: Czech Lymphoma Study Group | Conditions: Lymphoma, T-Cell, Peripheral | Phase 2 | Status: UNKNOWN